Halozyme Therapeutics, Inc. HALO

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

GlobeNewswire Inc. · 26d ago

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

GlobeNewswire Inc. · 74d ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

GlobeNewswire Inc. · 121d ago

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

GlobeNewswire Inc. · 130d ago

Halozyme Therapeutics Projects Sustained Growth Well Into 2040

Benzinga · 171d ago

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

Benzinga · 214d ago

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

The Motley Fool · 254d ago

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

GlobeNewswire Inc. · 262d ago

Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

GlobeNewswire Inc. · 272d ago

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

GlobeNewswire Inc. · 315d ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. · 326d ago

Halozyme (HALO) Q2 EPS Jumps 69%

The Motley Fool · 346d ago

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

GlobeNewswire Inc. · 463d ago

Needle Free Injectors Market Is Expected To Reach a Revenue Of USD 2,980.9 Million By 2033, At 8.1% CAGR: Dimension Market Research

GlobeNewswire Inc. · 614d ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks Investment Research · 751d ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks Investment Research · 758d ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks Investment Research · 761d ago

Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?

Zacks Investment Research · 764d ago

Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 766d ago

Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research · 767d ago

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Zacks Investment Research · 767d ago

This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Benzinga · 771d ago

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Zacks Investment Research · 771d ago

Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 772d ago

Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU

Zacks Investment Research · 772d ago